{"version":"1.0","provider_name":"Market Newsdesk","provider_url":"https:\/\/www.marketnewsdesk.com","author_name":"Newsdesk","author_url":"https:\/\/www.marketnewsdesk.com\/index.php\/author\/newsdesk\/","title":"Propanc Biopharma Provides Shareholder Update - Market Newsdesk","type":"rich","width":600,"height":338,"html":"<blockquote class=\"wp-embedded-content\" data-secret=\"HWaD2RqEhm\"><a href=\"https:\/\/www.marketnewsdesk.com\/index.php\/propanc-biopharma-provides-shareholder-update-3\/\">Propanc Biopharma Provides Shareholder Update<\/a><\/blockquote><iframe sandbox=\"allow-scripts\" security=\"restricted\" src=\"https:\/\/www.marketnewsdesk.com\/index.php\/propanc-biopharma-provides-shareholder-update-3\/embed\/#?secret=HWaD2RqEhm\" width=\"600\" height=\"338\" title=\"&#8220;Propanc Biopharma Provides Shareholder Update&#8221; &#8212; Market Newsdesk\" data-secret=\"HWaD2RqEhm\" frameborder=\"0\" marginwidth=\"0\" marginheight=\"0\" scrolling=\"no\" class=\"wp-embedded-content\"><\/iframe><script>\n\/*! This file is auto-generated *\/\n!function(d,l){\"use strict\";l.querySelector&&d.addEventListener&&\"undefined\"!=typeof URL&&(d.wp=d.wp||{},d.wp.receiveEmbedMessage||(d.wp.receiveEmbedMessage=function(e){var t=e.data;if((t||t.secret||t.message||t.value)&&!\/[^a-zA-Z0-9]\/.test(t.secret)){for(var s,r,n,a=l.querySelectorAll('iframe[data-secret=\"'+t.secret+'\"]'),o=l.querySelectorAll('blockquote[data-secret=\"'+t.secret+'\"]'),c=new RegExp(\"^https?:$\",\"i\"),i=0;i<o.length;i++)o[i].style.display=\"none\";for(i=0;i<a.length;i++)s=a[i],e.source===s.contentWindow&&(s.removeAttribute(\"style\"),\"height\"===t.message?(1e3<(r=parseInt(t.value,10))?r=1e3:~~r<200&&(r=200),s.height=r):\"link\"===t.message&&(r=new URL(s.getAttribute(\"src\")),n=new URL(t.value),c.test(n.protocol))&&n.host===r.host&&l.activeElement===s&&(d.top.location.href=t.value))}},d.addEventListener(\"message\",d.wp.receiveEmbedMessage,!1),l.addEventListener(\"DOMContentLoaded\",function(){for(var e,t,s=l.querySelectorAll(\"iframe.wp-embedded-content\"),r=0;r<s.length;r++)(t=(e=s[r]).getAttribute(\"data-secret\"))||(t=Math.random().toString(36).substring(2,12),e.src+=\"#?secret=\"+t,e.setAttribute(\"data-secret\",t)),e.contentWindow.postMessage({message:\"ready\",secret:t},\"*\")},!1)))}(window,document);\n\/\/# sourceURL=https:\/\/www.marketnewsdesk.com\/wp-includes\/js\/wp-embed.min.js\n<\/script>\n","description":"CEO Highlights Significant Progress Achieved &amp; Outlines Ambitious Plans for 2026 MELBOURNE, Australia, Jan. 13, 2026 (GLOBE NEWSWIRE) &#8212; Propanc Biopharma, Inc. (Nasdaq: PPCB) (\u201cPropanc\u201d or the \u201cCompany\u201d), a biopharmaceutical company focused on developing novel treatments for chronic diseases, including recurrent and metastatic cancer, today announced a shareholder update from its Chief Executive Officer and Cofounder, Mr. James Nathanielsz. In this update, Mr. Nathanielsz highlights the significant progress achieved during 2025 and outlines the Company\u2019s ambitious plans for 2026. With strong confidence, Propanc is executing its strategic roadmap for the clinical development of its lead asset, PRP, while further strengthening its scientific platform by expanding into additional therapeutic areas with high unmet medical need and advancing its pipeline, including the &hellip; Continue reading \"\"","thumbnail_url":"https:\/\/www.globenewswire.com\/newsroom\/ti?nf=OTYyNDYzNiM3MzU4MjIxIzIyOTExMTI="}